Rencontrez-nous à…
Toute l’actualité d’OTR3
Cacipliq 20 | Media Publications | RGTA technology
Overview of 10 years of practice with CACIPLIQ20® matrix therapy as a healing agent for hard to heal wounds: Efficacy, cost-effectiveness and future perspectives Background: Chronic, non-healing wounds remain a major challenge for health care practitioners and for society in general, both in terms of the enormous economic burden [...]
Dermatology | Media Publications
Merel Gansevoort 1 , SabineWentholt 1, Gaia Li Vecchi 1, Marjolein de Vries 1, Elly M. M. Versteeg 1, Bouke K. H. L. Boekema 2,3 , Agnes Choppin 4, Denis Barritault 4, Franck Chiappini 4 , Toin H. van Kuppevelt 1 and Willeke F. Daamen 1,* Fibrosis after full-thickness wound [...]
DERMAPLIQ
Dermapliq - Regenerating matrix-based therapy for chronic wound healing Suzanne L Groah, Alexander Libin, Miriam Spungen, Kim-Loan Nguyen, Earthaleen Woods, Marjan Nabili, Jessica Ramella-Roman, Denis Barritault The aim of this study was to determine whether a skin-specific bioengineered regenerating agent (RGTA) heparan sulphate mimetic (CACIPLIQ20) improves chronic wound healing. [...]
CLERAPLIQ
Clerapliq - Jama Ophtalmology clinical trial 2016 Oct 1;134(10):1169-1176. doi: 10.1001/jamaophthalmol.2016.3019. Ahmed M Bata , Katarzyna J Witkowska , Piotr A Wozniak , Klemens Fondi , Gerald Schmidinger , Niklas Pircher , Stephan Szegedi , Valentin Aranha Dos Santos , Anca Pantalon , René M Werkmeister, Gerhard Garhofer , [...]
CLERAPLIQ
Clerapliq - Topical Treatment with a New Matrix Therapy Agent Abdelouahab Aifa, Julie Gueudry, Alexandre Portmann, Agn`es Delcampe, and Marc Muraine PURPOSE. Neurotrophic keratopathy is a degenerative disease of the corneal epithelium resulting from impaired corneal innervation, possibly leading to perforation. We aimed to assess the efficacy and tolerance [...]
CLERAPLIQ
Clerapliq -Prise en charge médicale des ulcères cornéens avec RGTA Cas clinique - L'Essentiel Bertrand Michaud - Docteur vétérinaire Les ulcères cornéens sont des affections fréquemment rencontrées en pratique vétérinaire quotidienne. Leur trai- tement passe par la mise en évidence de l’origine de la lésion. Ainsi, le traitement devra [...]
News
OTR3 announces first patient enrolled in a Phase I study of OTR4132-MD in Acute Ischemic Stroke (AIS).
News
OTR3 announces first patient enrolled in a post market clinical follow up on Cacipliq 20®..
